Noveris Health Sciences Inc.
MYCOF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$42.74M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $42.74 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $2.37 |
| Beta | -5.44 |
| Outstanding Shares | 58,548,051 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -6.62 |
|---|---|
| PEG | 2.4 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-40.38
Consensus analyst estimateRevenue Estimate
$776,475
Consensus analyst estimateNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-40.38
Consensus analyst estimateRevenue Estimate
$239,758
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Noveris Health Sciences Inc.
3 employees
CEO: Jason Birmingham
Noveris Health Sciences Inc. operates as a biotechnology firm dedicated to the investigation, pharmaceutical development, and clinical evaluation of psilocybin-based products. Co-founded by Parente Carman, Damon Michaels, and Robert Rosc...